UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Early molecular response in patients (pts) with chronic myeloid
leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or
imatinib (IM) from DASISION.
Authors*: Neil P. Shah, Giuseppe Saglio, Andreas Hochhaus, Robyn Bilmes, Li Li, Jorge E. Cortes
Abstract #: 7055
Presentation Date/Time: Monday, June 6: 8:00 - 11:30 AM
Location: Hall A, poster Board #47
Poster Session - Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant.
Citation: J Clin Oncol 34, 2016 (suppl; abstr 7055)
Shah Research Interests: The Shah lab is interested in advancing targeted therapeutics for hematologic
malignancies through basic studies of in vitro and in vivo model systems to gain a better understanding of
the critical vulnerabilities of malignant cells, and through translational/clinical studies of samples obtained
from patients participating in early phase monotherapy clinical studies to identify, validate and override
mechanisms of resistance to these agents.
http://shah.ucsf.edu/
__________________________________________________________________________
Clinical, biologic, and outcome differences according to MIBG avidity
in children with neuroblastoma: A report from the Children’s Oncology
Group (COG).
Authors*: Steven G. DuBois, Rajen Mody, Collin Van Ryn, Arlene Naranjo, Susan G. Kreissman, David Baker,
Marguerite T Parisi, Barry L. Shulkin, John M. Maris, Vandana Batra, Julie R. Park, Katherine K. Matthay,
Gregory A Yanik
Abstract #: 10526
Presentation Date/Time: Monday, June 6: 8:00 - 11:30 AM
Location: Hall A, Poster Board #217
Session: Pediatric Oncology I
Citation: J Clin Oncol 34, 2016 (suppl; abstr 10526)
*UCSF authors in bold
70